

Governor

MARY T. BASSETT, M.D., M.P.H. Commissioner

KRISTIN M. PROUD
Acting Executive Deputy Commissioner

Medicaid Fee-for-Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective **8/11/2022**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- Flovent HFA, Lantus Solostar Pen, Kazano*, Lantus vial, Nesina* and Pentasa will be ADDED to the program
- Afinitor, Androgel pump, Androgel packet**, Catapres-TTS***, Diastat****, Diastat Acudial***, Entocort EC, Renagel, Tobradex suspension, Xeloda, and Zovirax will be REMOVED from the program.

In conformance with State Education Law, which intends patients receive the lower cost drug alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and "*Brand Medically Necessary*" on the prescription.

List of Brand Name Drugs included in this program (updated 7/26/2022)

Advair Diskus	Depakote Sprinkle	Nuvaring
Alphagan P 0.15%	Epipen, Epipen JR	Pentasa
Amitiza	Exelon Patch	ProAir HFA
Apriso	Firvanq	Rapamune solution
Azopt	Flovent HFA	Renvela tablet
Bethkis	Kazano	Restasis
Cellcept suspension	Kitabis Pak	Retin-A cream
Ciprodex	Lantus Solostar pen	Symbicort
Combigan	Lantus vial	Tegretol suspension
Concerta	Lialda	Tegretol XR
Copaxone 20mg	Nesina	Trileptal suspension

Drugs in this program may be subject to prior authorization requirements of other pharmacy programs. This list is subject to change.

^{*}Added based on 5/12/2022 DURB recommendation **removed 6/29/2022 due to market availability ***removed 5/25/2022 due to market availability ***removed from program 6/21/2022 due to market availability